Hoth Therapeutics Seeks 183% Boost in Equity Incentive Plan Shares

TL;DR

**HOTH is asking shareholders to approve a massive 183% increase in its equity incentive plan, signaling potential dilution and a focus on executive compensation over immediate shareholder returns.**

AI Summary

Hoth Therapeutics, Inc. (HOTH) has filed a DEF 14A for its 2025 Annual Meeting of Shareholders, scheduled for August 5, 2025, at 12:00 p.m. Eastern Time, to be held virtually. Key proposals include the election of directors, the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and a significant amendment to the 2022 Omnibus Equity Incentive Plan. The proposed amendment seeks to increase the number of shares reserved for issuance under the plan from 1,091,317 shares to 3,091,317 shares, representing a 183% increase. This expansion of the equity incentive pool could lead to substantial dilution for existing shareholders if fully utilized. The filing also includes an advisory vote on the frequency of future advisory votes on named executive officer compensation, indicating a focus on corporate governance and executive incentives.

Why It Matters

This DEF 14A filing is crucial for Hoth Therapeutics investors as it outlines proposals that could significantly impact shareholder value and corporate governance. The proposed increase of 2,000,000 shares in the 2022 Omnibus Equity Incentive Plan, from 1,091,317 to 3,091,317, represents potential dilution for existing shareholders, which could depress per-share earnings and stock price. For employees and executives, this expanded pool offers greater incentive compensation, potentially aligning their interests with long-term company growth, but also raising questions about executive compensation practices compared to competitors in the pharmaceutical preparations sector. Customers and the broader market will be watching how these governance decisions affect Hoth's ability to fund its pharmaceutical development pipeline and maintain competitive talent.

Risk Assessment

Risk Level: medium — The risk level is medium due to the proposed 183% increase in shares reserved for the 2022 Omnibus Equity Incentive Plan, from 1,091,317 to 3,091,317 shares. This substantial increase of 2,000,000 shares could lead to significant shareholder dilution, negatively impacting per-share metrics and stock value if these shares are issued.

Analyst Insight

Investors should carefully review the proposed amendment to the 2022 Omnibus Equity Incentive Plan and consider its potential dilutive effects on their holdings. Shareholders should vote against the plan amendment if they are concerned about excessive dilution or executive compensation, or in favor if they believe it is essential for attracting and retaining talent to drive future growth.

Key Numbers

• 3,091,317 shares — New total shares reserved for 2022 Omnibus Equity Incentive Plan (Increased from 1,091,317 shares, representing a 183% increase)
• 1,091,317 shares — Previous shares reserved for 2022 Omnibus Equity Incentive Plan (The baseline before the proposed amendment)
• 2,000,000 shares — Increase in shares for 2022 Omnibus Equity Incentive Plan (The absolute number of additional shares proposed for issuance)
• 183% — Percentage increase in shares for 2022 Omnibus Equity Incentive Plan (Calculated as (3,091,317 - 1,091,317) / 1,091,317)
• 2025-06-16 — Filing date of DEF 14A (Date the definitive proxy statement was filed with the SEC)
• 2025-08-05 — Conformed period of report / Annual Meeting date (The date for which the proxy statement is prepared and the meeting will be held)

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant for DEF 14A filing
• WithumSmith+Brown, PC (company) — Proposed independent registered public accounting firm for fiscal year ending December 31, 2025
• SEC (regulator) — Securities and Exchange Commission
• Nevada (regulator) — State of incorporation for Hoth Therapeutics, Inc.
• August 5, 2025 (date) — Date of the 2025 Annual Meeting of Shareholders
• 12:00 p.m. Eastern Time (time) — Time of the 2025 Annual Meeting of Shareholders
• 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036 (address) — Business address of Hoth Therapeutics, Inc.
• 001-38803 (number) — SEC file number for Hoth Therapeutics, Inc.

FAQ

Industry Context

Hoth Therapeutics operates in the pharmaceutical preparations sector. This industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from both established pharmaceutical giants and emerging biotechnology firms.

Regulatory Implications

The proposed increase in the equity incentive plan could be subject to scrutiny by regulatory bodies and investors concerned about excessive dilution. Compliance with SEC regulations for proxy solicitations and shareholder voting is paramount.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-08-05: 2025 Annual Meeting of Shareholders — Shareholders will vote on director elections, ratification of auditors, and amendments to the equity incentive plan.
• 2025-06-16: Filing of DEF 14A — Provides shareholders with detailed information regarding the annual meeting agenda and proposals.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC by a company soliciting shareholder votes. (This document outlines the proposals to be voted on at the Hoth Therapeutics 2025 Annual Meeting.)

2022 Omnibus Equity Incentive Plan

A plan established by Hoth Therapeutics to grant equity-based compensation to employees, directors, and consultants. (Shareholders are being asked to approve an amendment to increase the number of shares reserved under this plan, which could impact dilution.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to conduct an independent audit of its financial statements. (Shareholders will vote to ratify the appointment of WithumSmith+Brown, PC as the auditor for the fiscal year ending December 31, 2025.)

Advisory Vote on Executive Compensation

A non-binding shareholder vote on the compensation of the company's named executive officers. (The filing includes a vote on the frequency of these advisory votes, indicating a focus on corporate governance.)

Year-Over-Year Comparison

This filing pertains to the 2025 Annual Meeting, and direct year-over-year comparisons of financial metrics are not available within this proxy statement. However, the significant proposed increase in the equity incentive plan from 1,091,317 to 3,091,317 shares (a 183% rise) suggests a strategic shift towards incentivizing personnel, potentially anticipating future growth or operational needs.

From the Filing

0001213900-25-054759.txt : 20250616 0001213900-25-054759.hdr.sgml : 20250616 20250616160533 ACCESSION NUMBER: 0001213900-25-054759 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250805 FILED AS OF DATE: 20250616 DATE AS OF CHANGE: 20250616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251050089 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 DEF 14A 1 ea0243654-def14a_hoththerap.htm DEFINITIVE PROXY STATEMENT     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )   Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐   Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))   ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material under § 240.14a-12   HOTH THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter)     (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)   Payment of Filing Fee (Check all boxes that apply):   ☒ No fee required   ☐ Fee paid previously with preliminary materials   ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11               HOTH THERAPEUTICS, INC. 1177 Avenue of the Americas, 5 th Floor, Suite 5066 New York, NY 10036   NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 5, 2025   To the Shareholders of Hoth Therapeutics, Inc.:   The 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”) of Hoth Therapeutics, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”), will be held on Tuesday, August 5, 2025, at 12:00 p.m. Eastern Time. The 2025 Annual Meeting will be a completely virtual meeting which will be conducted via live webcast. You will be able to attend the 2025 Annual Meeting by visiting www.virtualshareholdermeeting.com/HOTH2025 .   In addition to voting by submitting your proxy prior to the 2025 Annual Meeting, you also will be able to vote your shares electronically during the 2025 Annual Meeting. Further details regarding the virtual meeting are included in the accompanying proxy statement. At the 2025 Annual Meeting, the holders of our outstanding common stock will act on the following matters:   1. To elect members of the Company’s board directors (the “Board”) to serve for a one-year term to expire at the 2026 annual meeting of shareholders;   2. To ratify the appointment of WithumSmith+Brown, PC (“Withum”) as our independent registered public accounting firm for the fiscal year ending December 31, 2025;     3. To approve an amendment to the Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (as amended, the “2022 Plan”) to increase the number of shares of common stock reserved for issuance thereunder to 3,091,317 shares from 1,091,317 shares (the “Plan Amendment”);         4. Approve, on an advisory basis, of the frequency of an advisory vote on named